Erratum: Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: Data from patients in the control arm of the STAMPEDE trial (JAMA Oncol (2015) DOI: 10.1001/jamaoncol.2015.4350);Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer

JAMA Oncology

Volumn 2, Issue 3, 2016, Pages 348-357

  James, Nicholas D ^a,b   Spears, Melissa R ^c   Clarke, Noel W ^d   Dearnaley, David P ^e   Mason, Malcolm D ^f   Parker, Christopher C ^e   Ritchie, Alastair W S ^c   Russell, J Martin ^g   Schiavone, Francesca ^c   Attard, Gerhardt ^e   De Bono, Johann S ^e   Birtle, Alison ^h   Engeler, Daniel S ⁱ   Elliott, Tony ^j   Matheson, David ^k   O'Sullivan, Joe ^l   Pudney, Delia ^m   Srihari, Narayanan ⁿ   Wallace, Jan ^o   Barber, Jim ^f   Syndikus, Isabel ^p   Parmar, Mahesh K B ^c   Sydes, Matthew R ^c   more..

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f VELINDRE CANCER CENTRE   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h ROYAL PRESTON HOSPITAL   (United Kingdom)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^j Greater Manchester Syphilis Group   (United Kingdom)

^k LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^l BELFAST CITY HOSPITAL   (United Kingdom)

^m SINGLETON HOSPITAL   (United Kingdom)

ⁿ ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^o BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^p CCO Liverpool Warrington Aintree   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ADVERSE EFFECTS; AGED; BLOOD; CONTROLLED STUDY; HUMAN; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; DOSE FRACTIONATION; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85010652979     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0032     Document Type: Erratum

References (24)

1. James ND, Sydes MR, Clarke NW, et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer-a multi-arm multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol). 2008;20(8):577-581.
2. James ND, SydesMR, Mason MD, et al; STAMPEDE investigators. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012;13 (5):549-558.
3. Sydes MR, James ND, Mason MD, et al. Flexible trial design in practice-dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials. 2011;12(suppl 1):A3.
4. Sydes MR, Parmar MK, James ND, et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE Trial. Trials. 2009;10:39.
5. Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012;13:168.
6. Attard G, Sydes MR, Mason MD, et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE Trial. Eur Urol. 2014;66(5):799-802.
7. James ND, SpearsMR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028-1038.
8. Parker CC, SydesMR, Mason MD, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013;111(5):697-699.
9. Widmark A, Klepp O, Solberg A, et al; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373(9660):301-308.
10. Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143-2150.
11. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology. 1995;194(2):349-355.
12. Parmar MK, Barthel FM, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. 2008;100(17):1204-1214.
13. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363-371.
14. Taori G, Ho KM, George C, et al. Landmark survival as an end-point for trials in critically ill patients-comparison of alternative durations of follow-up: an exploratory analysis. Crit Care. 2009; 13(4):R128.
15. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015;107(7):djv119.
16. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366-5373.
17. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787-794.
18. Warde P, Mason M, Ding K, et al; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378 (9809):2104-2111.
19. Parker CC, SydesMR, Mason MD, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE Trial. Clin Oncol (R Coll Radiol). 2013;25(5):318-320.
20. Myrehaug S, Chan G, Craig T, et al. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(4):e657-e662.
21. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781-1788.
22. Créhange G, Chen CP, Hsu CC, et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012;38(8):956-967.
23. Lawton CA, DeSilvio M, RoachMIII, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69(3):646-655.
24. RoachMIII, DeSilvio M, Lawton C, et al; Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003; 21(10):1904-1911.